Revolutionizing the Way Genetic Discoveries Are Made

Genomenon means “born out of need” in ancient Greek. In his clinical practice and genomic research, our co-founder Dr. Mark Kiel experienced the painfully slow and time-consuming process used by the industry to manually curate patients’ DNA variants.
Genomenon was founded to address this pressing need for faster, more comprehensive variant curation, and to accelerate genomic interpretation a hundredfold.

At the time Genomenon was started, interpretation of genomic data resulting from next-generation DNA sequencing (NGS) was frustratingly inefficient and error-prone due to the time consuming, manual approach required to search and analyze the rapidly growing body of medical literature for disease-related genes and variants.

To launch Genomenon, Mark found like-minded experts dedicated to connecting patient DNA data with the billions of dollars worth of medical research that was previously impossible to organize at scale, and too challenging to interpret quickly and accurately for clinical genomics.

The Genomenon team built the Mastermind Genomic Search Engine and Database, which contains all the disease-gene-variant relationships found across the scientific literature. The technology developed to accomplish this feat is revolutionizing the way genetic and cancer diagnoses and discoveries are made. Mastermind makes it easy to get rapid insight into relevant literature for clinical decision-making, genomic research, and pharmaceutical drug discovery.

Mastermind now empowers scientists and researchers at pharmaceutical companies and universities to more thoroughly understand diseases at a molecular level. Doctors in over 100 countries are using Mastermind to rapidly connect their patient’s variants with the published genomic research to more effectively treat cancer patients and diagnose babies with rare diseases